Relmada Therapeutics, Inc.
RLMD
$0.39
-$0.0083-2.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 19.04% | 22.48% | 32.74% | 34.34% | 37.09% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.34% | -19.57% | -17.00% | 4.65% | 3.29% |
| Change in Net Operating Assets | -151.42% | 116.10% | 122.15% | 49.50% | -70.92% |
| Cash from Operations | -0.19% | 31.16% | 47.93% | 52.23% | 50.23% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.20% | 16.81% | -48.11% | -70.60% | 155.67% |
| Cash from Investing | 2.20% | 16.81% | -48.11% | -70.60% | 155.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 579.61% | -62.36% | -98.33% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -191.47% | -157.04% | -138.16% | -138.16% | -130.44% |
| Cash from Financing | 58.98% | -91.80% | -87.42% | -99.18% | -100.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.01% | 85.44% | 45.67% | -71.82% | 96.66% |